Fløisand, Yngvar http://orcid.org/0000-0001-7267-1944
Schroeder, Mark A.
Chevallier, Patrice
Selleslag, Dominik
Devine, Steven
Renteria, Anne S.
Mohty, Mohamad http://orcid.org/0000-0002-7264-808X
Yakoub-Agha, Ibrahim http://orcid.org/0000-0003-4524-8782
Chen, Chunlin
Parfionovas, Andrejus
Quadri, Syed
Jansson, Johan
Akbari, Mona
Chen, Yi-Bin http://orcid.org/0000-0002-9554-1058
Article History
Received: 21 August 2020
Revised: 23 April 2021
Accepted: 12 May 2021
First Online: 9 June 2021
Compliance with ethical standards
:
: YF: consultancy fees from Takeda, Celgene, Novartis, Pfizer, Otsuka and Astellas (advisory boards and speaker). MAS: advisory board and received honorary or consultant fees from (year of last engagement): Amgen (2017), Astellas (Feb 2019), Dova pharmaceuticals (May 2019), FlatIron Inc (June 2019), GSK (October 2019), Gilead Sciences (2017), Incyte (May 2018), Novo Nordisk (2018), Partners Therapeutics (Nov 2018), Pfizer (July 2018), Sanofi Genzyme (2017). Speaker bureau (all terminated August 2019): Abbvie, Merck, Takeda. Research funding: Incyte, Seattle Genetics, Janssen, Genzyme Sanofi, Celgene. PC, DS, SD, ASR: nothing to disclose. MM has received fees for consultancy and speaker bureau participation, honoraria and research funding from Sanofi, Janssen, Amgen, Takeda, Celgene, GSK, Jazz, Adaptive, Stemline, BMS, and Novartis. IYA received honorarium from Takeda, Celgene, Novartis, Janssen, Gilead/Kite. CC was an employee of Millennium Pharmaceuticals Inc. at the time the study was performed. AP was an employee of Millennium Pharmaceuticals Inc. at the time the study was performed. He is currently the Associate Director of Biostatistics at Sage Therapeutics. SQ and JJ are employees of Millennium Pharmaceuticals Inc. MA was a Takeda employee at the time the study was performed; She is currently a Senior Medical Director at AbbVie. YBC: consulting fees for Takeda, Magenta, Abbvie, Daiichi, Equilium, Incyte, Pharmacyclics, Celularity.
: This study was conducted in accordance with Good Clinical Practice regulations and guidelines, the Declaration of Helsinki, and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, in addition to all applicable local or regional regulatory requirements [CitationRef removed,CitationRef removed]. Relevant documentation was supplied to the IRB or IEC for review and approval of the protocol.